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Rates of HIV infection in sub-Saharan Africa remain 
stubbornly high,[1] despite considerable investment 
in an array of HIV prevention interventions. The 
solution to accelerating and sustaining the decline in 
new infections may be found in the addition of new 
interventions to the ‘tool kit’. These include early antiretroviral (ARV) 
treatment for prevention, innovative behaviour change methods, 
‘key population’ intervention packages, vaccines and passive 
immunisation. While all of these have potential, their utility remains 
unproven.
The most recent breakthrough is pre-exposure prophylaxis (PrEP), 
where ARVs are administered to someone at risk of sexually acquiring 
HIV. To date, five trials have demonstrated varying levels of efficacy, 
four using oral ARVs and one using a vaginal gel or microbicide, 
with a confirmatory trial underway. [2-6] While efficacy was clearly 
demonstrated by these trials, many questions remain concerning 
practical rollout and implementation of PrEP. Guidelines for oral PrEP 
use have been developed, but operations research is required to validate 
their effectiveness,[7-10] prompting the World Health Organization to 
call for demonstration projects.[10]
In South Africa (SA), where the HIV epidemic remains the 
largest in the world,[1] there is a need to reduce new infections. The 
current South African National Strategic Plan on HIV, sexually 
transmitted infections and tuberculosis (NSP) specifically calls for 
the consideration of new modalities for HIV prevention, including 
PrEP.[11]
So, where does PrEP fit within the real-world SA context? Who 
would get it, and how and where would it be delivered? Will people 
take it, and how would we ensure that it doesn’t further contribute 
to the problem by generating behavioural disinhibition or resistant 
strains of HIV? Can we pay for it, and is it cost-effective?
‘If you take it, it works’:  
The importance of adherence
The single biggest Achilles heel in all the PrEP studies has been 
poor levels of adherence. The FemPrEP trial and two arms of the 
VOICE trial were stopped early owing to futility associated with poor 
adherence.[12-14] Recent results from the remaining active arm of the 
VOICE trial showed no effect, again due to lack of adherence.[15] In 
the successful trials, blood and genital secretion drug levels correlated 
with protection. Over 90% protection was observed in study patients 
with high adherence,[16] but the majority of patients throughout the 
trials did not achieve this level.
The low levels of adherence observed in clinical trials need to be 
understood, and are currently speculative. In PrEP trials, younger 
women who are single and at higher risk of HIV have much lower 
adherence than older, married women, despite intensive adherence 
counselling and support. Predictably, some prevention research 
suggests that those who perceive themselves to be at high risk have 
the best adherence.[17,18] In a clinical trial, advice that the products 
are either unproven or are placebos may have had an impact on 
adherence. Less is known about how messages will affect uptake 
and patterns of use once PrEP is broadly available. Conceptually, 
contraception is similar in that it is designed to prevent an unwanted 
event resulting from sexual activity. As with contraception,[19] it would 
seem that education, proof of efficacy, motivation and recognition of 
risk drive adherence.
In addition to low efficacy, low adherence could result in the emergence 
of ARV resistance. There have been few HIV transmission cases in 
the trials, and modelling has shown that ARV treatment will be the 
prime generator of ARV resistance, even with widespread PrEP. [20] To 
avoid resistance, HIV pre-PrEP testing and regular monitoring must 
be rigorous enough to catch breakthrough infections. Solutions to 
alleviate daily adherence issues could be found in intermittent dosing, 
or alternative routes of administration such as injections or a long-
acting ARV-releasing vaginal ring.
Ability to measure adherence is another sticking point. The trials 
have clearly indicated that self-reported adherence is not predictive 
of actual use, as illustrated by plasma and vaginal drug levels.[2-4,12,15] 
However, in a real-world application of PrEP, laboratory-based 
adherence measurements may not be practical or cost-effective.
Who gets it?
PrEP will be most appropriate for individuals at highest HIV risk, 
but it is not entirely clear how best to reach them. In a concentrated 
epidemic, where transmissions are centralised to one particular group 
or groups, delivering focused messages is relatively straightforward. 
In SA, where the epidemic is generalised and transmissions occur in 
the broader population, delivering tailored and targeted interventions 
becomes a major challenge.
Frequently individuals do not identify themselves as at high risk, and 
some groups at risk, such as young women, are not easy to access through 
conventional programmes. As research has shown, those who don’t see 
themselves as being at risk have the worst adherence. [12] PrEP is not 
likely to be the main prevention method of choice for most individuals 
for extended periods of time, so other options must also be available. 
For instance, a woman might use PrEP at a time when she feels she is at 
higher risk, and then stop taking it and choose another prevention option 
better suited to her changing needs. Furthermore, it is conceivable that 
the ‘worried well’ will aggressively seek out this intervention, despite 
already accessing other effective prevention modalities such as condoms.
In SA, high-risk ‘key populations’ include adolescent girls and 
young women, sex workers, men who have sex with men (MSM), 
discordant couples and truckers, all of whom face various barriers to 
access including stigma, criminalisation and lack of supportive service 
delivery infrastructure.[21] If they are to be the focal point for PrEP, it will 
be imperative to assess how best to introduce PrEP into programmes 
where these key populations can be accessed and supported.
Delivering PrEP 
If the main recipients of PrEP are ‘key populations’, service delivery 
sites must include comprehensive HIV prevention programmes 
tailored to these groups, with options to suit various prevention 
needs. The service provision will need to be efficient, sophisticated, 
reliable and contextually relevant.
PrEP is likely to be complex to deliver. Because certain renal 
and viral hepatitis conditions are contraindications, oral PrEP has 
relatively intensive testing and monitoring requirements. Restricting 
PrEP to being obtained in specialised environments or through 
general practitioners would mean that fewer people would have access 
and cost-effectiveness would be reduced. However, broader access 
within the primary care state sector, already overloaded with multiple 
programmes, seems unlikely to be an option in the near future. Noting 
all these constraints, it seems that a PrEP intervention would be best 
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integrated into an already successful key population programme 
embedded within communities where testing and care facilities exist.
In addition to considering the facility and human resource 
requirements for delivering PrEP, the approach to testing will also 
be an important element to get right. Frequent testing is necessary 
to prevent infected people from starting PrEP and to prevent those 
who contract HIV while on PrEP from developing and possibly 
transmitting resistant virus, especially as current PrEP medication 
is used in first-line ARV regimens. Some qualitative studies have 
indicated that consumers would be willing to test regularly, but 
these studies were conducted before any products were proven 
efficacious. [22] At this point it is hard to predict whether responses will 
translate to real-world application. Reliable home tests may present a 
solution to the burden of testing, as it may be possible for individuals 
to test themselves.[23] This should be the topic of second-phase 
operations research once the field has tested PrEP’s programmatic 
viability under more conservative circumstances.
PrEP use also creates anxiety about potential behavioural 
disinhibition. So far, data from male circumcision studies, from the 
PrEP and treatment for prevention trials and from ARV rollout do 
not support this concern.[24,25] Although some surveys, interviews 
and focus groups conducted in various user audiences have suggested 
that users may decide to ignore condoms once PrEP is offered,[25,26] 
ultimately there will be no way to answer this question until it has 
been tested in a real-world environment.
Can we foot the bill?
As with any new technology, the question of affordability, cost-
effectiveness and competitive budgeting is central to the use of PrEP. 
In particular there are concerns about whether money will be taken 
from the treatment budget to pay for PrEP, posing an ethical dilemma 
in deciding whether healthy individuals should be prioritised over 
the sick. The ethics of PrEP are important and have been evaluated 
elsewhere.[27,28] We argue that the discussion should focus on defining 
the right method mix and how to support it.
Some cost-effectiveness analyses have shown that while PrEP is 
expensive, there may still be a place for it in terms of impact and reducing 
the future costs of treatment and HIV management.[29] It is important to 
note that to date, analyses have been conducted employing some major 
assumptions about cost structure, delivery mechanisms, population 
size and efficacy. Now that we have more data from the trials and an 
opportunity to collect cost information from actual demonstration 
programmes, we can better assess whether PrEP is worth it.
Conclusions
While PrEP provides a new technology in the prevention tool kit, 
it is a complex prevention intervention. Evaluations targeting key 
populations who are already accessing health programmes must be 
the next step in understanding its role. In addition, GPs can start 
prescribing the medication to selected patients. Piloting PrEP in these 
contexts will allow for cost-effectiveness modelling and produce 
evidence on which to base future policy and programming decisions.
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